This study was done in collaboration with the Departments of Immunology and Nephrology at the
“It is fantastic that Devyser’s technology has the potential to improve monitoring and management of patients that have multiple kidney transplantations,” said Fredrik Alpsten, CEO at Devyser. “Devyser strives to innovate and be a pioneering leader of diagnostic solutions. We are proud to be part of making a difference for kidney transplanted patients.”
With about 92,000 kidney transplantations performed each year globally, significant numbers of patients need a second kidney transplant, requiring technologies that work when a patient has multiple kidneys from separate donors.
Follow the link below to read the article at the Frontier of Immunology: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1282521/full
© Modular Finance, source